S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:YMTX

Yumanity Therapeutics - YMTX Stock Forecast, Price & News

$7.00
-0.83 (-10.60%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.00
$8.22
50-Day Range
$1.68
$7.83
52-Week Range
$0.95
$3.78
Volume
15,023 shs
Average Volume
473,083 shs
Market Capitalization
$75.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

YMTX stock logo

About Yumanity Therapeutics (NASDAQ:YMTX) Stock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMTX Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
See More Headlines
Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMTX Company Calendar

Last Earnings
8/12/2021
Today
1/28/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:YMTX
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
$-39,500,000.00
Net Margins
-660.61%
Pretax Margin
-660.61%

Debt

Sales & Book Value

Annual Sales
$8.04 million
Book Value
$2.28 per share

Miscellaneous

Free Float
9,504,000
Market Cap
$75.99 million
Optionable
Not Optionable
Beta
0.32

Key Executives

  • Dr. Richard Peters M.D. (Age 59)
    Ph.D., CEO, Pres & Director
    Comp: $896.1k
  • Dr. Vikram Khurana M.D.
    Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery Biology
  • Ms. Chee Yeun Chung Ph.D.
    Scientific Co-Founder & Associate Director of Discovery Biology
  • Ms. Marie Epstein CPA
    VP of Fin.
  • Mr. Michael D. Wyzga (Age 33)
    SVP, CFO & Treasurer
  • Mr. Devin Whittemore Smith (Age 54)
    SVP, Gen. Counsel & Sec.













YMTX Stock - Frequently Asked Questions

How have YMTX shares performed in 2023?

Yumanity Therapeutics' stock was trading at $6.35 at the start of the year. Since then, YMTX shares have increased by 10.2% and is now trading at $7.00.
View the best growth stocks for 2023 here
.

When is Yumanity Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our YMTX earnings forecast
.

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) announced its quarterly earnings data on Thursday, August, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.19. The firm earned $2.11 million during the quarter, compared to analysts' expectations of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

What is Yumanity Therapeutics' stock symbol?

Yumanity Therapeutics trades on the NASDAQ under the ticker symbol "YMTX."

How do I buy shares of Yumanity Therapeutics?

Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Yumanity Therapeutics' stock price today?

One share of YMTX stock can currently be purchased for approximately $7.00.

How much money does Yumanity Therapeutics make?

Yumanity Therapeutics (NASDAQ:YMTX) has a market capitalization of $75.99 million and generates $8.04 million in revenue each year. The company earns $-39,500,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How can I contact Yumanity Therapeutics?

Yumanity Therapeutics' mailing address is 40 GUEST STREET SUITE 4410, BOSTON MA, 02135. The official website for the company is www.yumanity.com. The company can be reached via phone at (617) 409-5300 or via email at lroth@burnsmc.com.

This page (NASDAQ:YMTX) was last updated on 1/28/2023 by MarketBeat.com Staff